Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
19 avr. 2023 16h30 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
13 mars 2023 16h05 HE
|
Viracta Therapeutics, Inc.
Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the...
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
08 mars 2023 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
07 févr. 2023 16h05 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
19 janv. 2023 08h30 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
08 janv. 2023 13h00 HE
|
Viracta Therapeutics, Inc.
Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into fourth dose...
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
30 nov. 2022 18h10 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces New Employment Inducement Grant
21 nov. 2022 17h08 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Announces New Employment Inducement Grant
14 nov. 2022 16h41 HE
|
Viracta Therapeutics, Inc.
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact...
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
10 nov. 2022 16h05 HE
|
Viracta Therapeutics, Inc.
Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV+) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to...